אודות פרק זה
Prof Anton Hagenbeek (Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands) talks to ecancertv at EHA 2015 about immunoconjugates, the latest targeted treatments in Hodgkin's lymphoma. He also suggests that patients with Hodgkin's disease partake in clinical trials.
ecancer's filming at EHA has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
ecancer's filming at EHA has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
אנגלית
ארצות הברית
תעתיק 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
פרקים אחרים בפודקאסט הזה
Dr Ehninger (University Hospital Dresden, Dresden, Germany) presents on the results of a phase II randomised study on the safety and efficacy of sorafenib in leukaemia at a press conference at EHA 2015.
Dr Olga Guryanova (Memorial Sloan Kettering Cancer Center, New York, USA) presents, at a press conference at EHA 2015, the findings of her work looking at the role of mutant DNMT3A in acute myeloid leukaemia (AML) pathogenesis and chemoresistance.
At a press conference at EHA 2015, Dr Mesa (Mayo Clinic Cancer Center, Scottsdale, USA) presented new data from the Phase 3 PERSIST-1 study which showed that pacritinib is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with…
Dr Hoffmann (Ludwig Maximilian University, Munich, Germany) talks to ecancertv at EHA 2015 about a web-based registry to record all newly-diagnosed chronic myeloid leukaemia (CML) patients in 20 European countries or pre-specified regions covering overall 92.5 million inhabitants.
The researchers…
הצהרה: הפודקאסט והגרפיקה המוטבעים בדף זה הם מ-ecancer, שהוא רכושו של בעליו ואינו קשור או מאושר על ידי Listen Notes, Inc.
